Some of the best links we picked up around the internet

Some of the best links we picked up around the internet

Fate Therapeutics announced this week that enrolment is underway for a Phase 1 trial of FT-825/OMO-8250 in advanced HER2-expressing solid tumours.

In this clinical trial roundup, we look at ongoing trials of gene-edited therapies for cancers of the gastrointestinal tract.

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

This week’s IND update looks at FT536, a gene-edited natural killer cell therapy developed by Fate Therapeutics for the treatment of multiple solid...

Verve Therapeutics demonstrates preclinical proof-of-concept with support from Beam Therapeutics

Multiple new deals and developments and new base editor data from Intellia Therapeutics